13F Insight
DOSSIER · 13F-HR · Q2 2026

FARALLON CAPITAL MANAGEMENT LLC

$21.7B in tracked AUM across 89 positions as of Q2 2026.

FC
CIK 0000909661 · last filed Jun 30, 2026
Total AUM
$21.7B
as of Q2 2026
Holdings
89
—
positions
Whale Score
82
82
strong
Activity
—
no data
changes this Q
AI Analysis · Q2 2026

FARALLON CAPITAL MANAGEMENT LLC filed Q1 2026 13F-HR with $21.2B in disclosed U.S. equity holdings The portfolio is led by Healthcare exposure, with top positions including 78462F953 (8.5%), RVMD (7.5%), AMZN (5.0%). Quarter-over-quarter activity shows 50 new entries and 2 exits, with a net additive posture across 52 changed positions. Notable new position: 78462F953 $$0.0B.

FARALLON CAPITAL MANAGEMENT LLC reports $21.2B in U.S. equity holdings for Q1 2026, anchored by a Healthcare-centric allocation. The top five positions by value span 78462F953 + RVMD + AMZN + MSFT + G0403H108, collectively representing a meaningful concentration within the disclosed book.

Core Holdings

  • 78462F953 (STATE STR SPDR S&P 500 ETF T) — $1.5B (8.5%)
  • RVMD (REVOLUTION MEDICINES INC) — $1.3B (7.5%)
  • AMZN (AMAZON COM INC) — $0.9B (5.0%)
  • MSFT (MICROSOFT CORP) — $0.9B (4.9%)
  • G0403H108 (AON PLC) — $0.8B (4.6%)
Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
SPY
STATE STR SPDR S&P 500 ETF T
$4.5B6.0M20.7%02
RVMD
REVOLUTION MEDICINES INC
$2.5B13.6M11.7%03
EA
ELECTRONIC ARTS INC
$1.6B7.9M7.5%04
BBIO
BRIDGEBIO PHARMA INC
$800M10.7M3.7%05
PTGX
PROTAGONIST THERAPEUTICS INC
$778M6.3M3.6%06
EXEL
EXELIXIS INC
$733M13.5M3.4%07
LQDA
LIQUIDIA CORPORATION
$667M8.4M3.1%08
AMZN
AMAZON COM INC
$628M2.6M2.9%09
LNTH
LANTHEUS HLDGS INC
$619M5.6M2.9%10
NTRA
NATERA INC
$602M2.2M2.8%

Filing history

2026Q2Jun 30
$21.7B▲ 13.7%
89 positionsView →2026Q1Mar 31
$19.1B▼ 17.5%
173 positionsView →2025Q4Dec 31
$23.1B▼ 5.4%
154 positionsView →2025Q3Sep 30
$24.4B▲ 4.8%
144 positionsView →2025Q2Jun 30
$23.3B▲ 128.0%
142 positionsLocked2025Q1Mar 31
$10.2B▼ 48.4%
91 positionsLocked2024Q4Dec 31
$19.8B▼ 5.6%
139 positionsLocked2024Q3Sep 30
$21.0B▼ 3.1%
155 positionsLocked2024Q2Jun 30
$21.6B▼ 2.8%
159 positionsLocked2024Q1Mar 31
$22.3B▲ 4.8%
170 positionsLocked2023Q4Dec 31
$21.2B▼ 0.7%
155 positionsLocked2023Q3Sep 30
$21.4B▲ 7.3%
163 positionsLocked
Showing 12 of 100